PXAI Audio Feed
31/03 11:46 yahoo.com

CRISPR (CRSP) Rated Overweight on Gene Editing Growth

CRISPRgene editingCRSPoverweight ratingbiotechtherapeutic technology
31/03 11:30 statnews.com

STAT+: Biotech VCs move upstream in China’s scientific pipelines as competition grows fiercer

US venture capitalChina biotechupstream investmentscientific pipelineRA CapitalLegend Biotech
31/03 10:02 defenseworld.net

Senti Biosciences (NASDAQ:SNTI) Price Target Cut to $11.00 by Analysts at Chardan Capital

Senti Biosciencesprice targetChardan Capitalstock ratingsNASDAQinvestment analysis
31/03 09:47 defenseworld.net

NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of “Hold” by Brokerages

NovoCureNASDAQHold ratingprice targetanalyst consensusbiotech
31/03 09:31 defenseworld.net

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Raised to $9.00 at Bank of America

Rocket Pharmaceuticalsprice targetBank of AmericaCantor FitzgeraldMorgan StanleyGoldman Sachs
31/03 09:24 defenseworld.net

Viridian Therapeutics (NASDAQ:VRDN) Given New $32.00 Price Target at Needham & Company LLC

Viridian TherapeuticsVRDNprice targetanalyst ratingsbiotech
31/03 09:18 defenseworld.net

Analyzing Applied Dna Sciences (NASDAQ:BNBX) & 20/20 Biolabs (NASDAQ:AIDX)

Applied DNA Sciences20/20 Biolabsanalyst ratingsinstitutional ownershipvaluationdividends
31/03 08:56 defenseworld.net

Analysts’ Recent Ratings Changes for AnaptysBio (ANAB)

AnaptysBioAnABanalyst ratingsprice targetbiotech stock
31/03 08:32 defenseworld.net

Aprea Therapeutics (NASDAQ:APRE) versus Ocugen (NASDAQ:OCGN) Head-To-Head Comparison

small‑cap biotechAprea TherapeuticsOcugenanalyst ratingsprice targetupside potential
31/03 08:32 defenseworld.net

Aprea Therapeutics (NASDAQ:APRE) versus Ocugen (NASDAQ:OCGN) Head-To-Head Comparison

small‑cap biotechAprea TherapeuticsOcugenanalyst ratingsprice targetupside potential
Comments
Loading...
0